mtc

(redirected from Medullary thyroid cancer)
Also found in: Medical.

mtc

A Modula-2 to C translator.

ftp://rusmv1.rus.uni-stuttgart.de/soft/Unixtools/compilerbau/mtc.tar.Z.

MTC

(Machine Type Communications) Cellular transmission from machines rather than people. MTC was coined by the 3G/4G term (see 3GPP).
References in periodicals archive ?
If you have a family history of thyroid cancer a blood test can reveal a genetic mutation for familial medullary thyroid cancer.
Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development.
NRASQ61R mutation-specific immunohistochemistry also identifies the HRASQ61R mutation in medullary thyroid cancer and may have a role in triaging genetic testing for MEN2.
The company is advancing four programmes in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development.
David Smith's next presentation was on Medullary Thyroid Cancer and he discussed in detail the diagnostic modalities, surgical management besides post-operative follow up.
Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
Vaughan "I've spoken to my surgeon and as it needs a longer slot than the other op it probably won't be on the 30th but it'll be within the week still," said Teresa, who has medullary thyroid cancer.
In December 2013, EMA recommended for approval another cabozantinib-containing medicine (Cometriq) to treat adults with medullary thyroid cancer.
Hutchison China MediTech has initiated an open-label Phase II trial to evaluate the efficacy and safety of sulfatinib (HMPL-012) in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (DTC) or medullary thyroid cancer (MTC) in China.
It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects.
Also considering her medical history as well as that of her family, the doctors also recommended that Arroyo undergo a Positron Emission Tornography (PET) scan; Tumor Markers-Alpha Feto Protein for liver cancer; CEA CA 15-3 for breast cancer; 19-9 for the pancreas; and CA 125 Calcitronin for medullary thyroid cancer.